Table A1.
Variable | No. | % |
---|---|---|
NSABP B-28 ER+ patients (n = 1065) | ||
Age, years | ||
< 50 | 511 | 48.0 |
≥ 50 | 554 | 52.0 |
Tumor size, cm | ||
≤ 2.0 | 483 | 45.4 |
2.1-4.0 | 467 | 43.8 |
≥ 4.1 | 115 | 10.8 |
Positive nodes, No. | ||
1-3 | 722 | 67.8 |
4-9 | 300 | 28.2 |
≥ 10 | 43 | 4.0 |
Central tumor grade | ||
Well | 120 | 11.3 |
Moderate | 499 | 46.9 |
Poor | 405 | 38.0 |
Unknown | 41 | 3.8 |
Treatment | ||
AC | 519 | 48.7 |
AC→P | 546 | 51.3 |
Surgery type | ||
Lumpectomy | 461 | 43.3 |
Mastectomy | 604 | 56.7 |
NSABP B-14 tamoxifen-treated patients (n = 668) | ||
Age, years | ||
< 50 | 194 | 29.0 |
≥ 50 | 474 | 71.0 |
Tumor size, cm | ||
≤ 2.0 | 414 | 62.0 |
2.1-4.0 | 220 | 32.9 |
≥ 4.1 | 34 | 5.0 |
Central tumor grade | ||
Well | 224 | 33.5 |
Moderate | 296 | 44.3 |
Poor | 148 | 22.2 |
Abbreviations: AC, doxorubicin plus cyclophosphamide, AC→P, doxorubicin plus cyclophosphamide followed by paclitaxel; ER, estrogen receptor; NSABP, National Surgical Adjuvant Breast and Bowel Project.